HRSA is reimbursing for COVID-19 testing and treatment for uninsured patients


Since the beginning of the pandemic, community health centers have responded to and met the needs of their communities. NACHC released HRSA’s updated COVID-19 stats. Since August 8, 2020, 96 percent of health centers have the ability to test for COVID-19 and 80 percent have walk-up or drive-up testing. More than 2.8 million health center patients have been tested for COVID-19 since April 3, 2020.

HRSA has funded and created a way for providers to be reimbursed for the patients they have either tested and/or treated for COVID-19.

The following includes eligible services for HRSA reimbursement:

  • Specimen collection, diagnostic and antibody testing
  • Testing-related visits – from an office, urgent care, emergency room or telehealth
  • Treatment – from an office, using telehealth, emergency room, inpatient, outpatient/observation, skilled nursing facility, long-term acute care (LTAC), acute inpatient rehab, home health, DME, emergency ambulance transportation, non-emergent patient transfers via an ambulance and (when available) FDA approved drugs for COVID-19 treatment and are provided as part of an inpatient stay
  • FDA approved vaccine (when available)

The following includes the services that are not eligible for HRSA reimbursement:

  • Services not covered by Medicare
  • Any treatment without a COVID-19 primary diagnosis, except for pregnancy when the COVID-19 code may be listed as secondary
  • Hospice services
  • Outpatient prescription drugs

When submitting COVID-19 claims to HRSA, remember that claims are subject to Medicare’s timely filing requirements and all claims that are submitted must be complete and final. These claims cannot be reworked if they are denied.

Additionally, the COVID-19 claims reimbursement to health care providers and facilities for testing and treatment of the uninsured is now available!

Click here for FAQs and here for the portal.

Click here for more information.

The HRSA COVID-19 billing can be confusing. We can help!

Previous Post
COVID-19’s effect on pediatric patients
Next Post
Manufacturers are challenging HRSA’s 2010 340B Pharmacy guidance

You must be logged in to post a comment.
Join the ACE community!
Subscribe to receive our latest news and updates
delivered straight to your inbox.
Get our latest news & updates straight to your inbox